<DOC>
	<DOCNO>NCT01989520</DOCNO>
	<brief_summary>Study investigate relative bioavailability five different formulation AZD5069</brief_summary>
	<brief_title>Study Investigate Relative Bioavailability Five Different Formulations AZD5069</brief_title>
	<detailed_description>An Open-label , Single Centre Relative Bioavailability Study With Adaptive Design Comparing 5 Solid Oral AZD5069 Formulations After Single Dose Administration Healthy Volunteers</detailed_description>
	<criteria>1 . Healthy male and/or female volunteer age 18 50 year ( inclusive ) . 2 . Nonsmokers exsmokers smoke history last 3 month prior screen . 3 . Body mass index ( BMI ) ≥18.0 ≤30.0 kg/m2 calculate height weight screening ; minimum ( min ) weight 50 kg maximum ( max ) weight 100 kg . 4 . Healthy volunteer neutrophil count within laboratory range screening . 1 . A definite suspect personal history severe allergy , intolerance hypersensitivity ongoing allergy drug similar chemical structure class AZD5069 and/or excipients , judge clinically relevant Investigator . 2 . Healthy volunteer previously receive AZD5069 . 3 . Volunteers latent tuberculosis suggest history judge Investigator ; confirmatory test eg , Quantiferon ( R ) TB Gold may do require . 4 . Volunteers receive live liveattenuated vaccine 2 week prior first administration IP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Relative bioavailability , Healthy volunteer , Neutrophils</keyword>
</DOC>